Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 pooled ECHO/THRIVE subanalysis

AIDS Patient Care and STDs

Volumn 28, Issue 4, 2014, Pages 168-175

  Behrens, Georg ^a   Rijnders, Bart ^b   Nelson, Mark ^c   Orkin, Chloe ^d   Cohen, Calvin ^e   Mills, Anthony ^f   Elion, Richard A ^g   Vanveggel, Simon ^h   Stevens, Marita ^h   Rimsky, Laurence ^h   Thorpe, David ⁱ   Bosse, Matthew ⁱ   White, Kirsten ^j   Zhong, Lijie ^j   DeMorin, Jennifer ^j   Chuck, Susan K ^j  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e Boston Community Research Initiative of New England   (United States)

^f Anthony Mills MD Inc   (United States)

^g Whitman Walker Clinic   (United States)

^h JANSSEN RESEARCH FOUNDATION   (Belgium)

ⁱ Gilead Sciences Europe Limited   (United Kingdom)

^j GILEAD SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA AMYLASE PANCREAS ISOENZYME; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RILPIVIRINE; TRIACYLGLYCEROL; VIRUS RNA;

ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; ADULT; AGED; ANXIETY; ARTICLE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MOOD CHANGE; MULTICENTER STUDY; NIGHTMARE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BENZOXAZINES; DEOXYCYTIDINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NITRILES; ORGANOPHOSPHONATES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84898717720     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2013.0310     Document Type: Article

References (20)

1. European AIDS Clinical Society (EACS). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. Version 7.0-October 2013; 2012:1-82.
2. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the Office of AIDS Research Advisory Council (OARAC). Revised 12 February 2013. Available at: Http://aidsinfo.nih.gov/guidelines. Accessed February 12, 2013.
3. SUSTIVA-(efavirenz) capsules and tablets for oral use. US Prescribing Information. Bristol-Myers Squibb Company. Princeton, NJ, May 2013.
4. Molina JM, Clumeck N, Redant K, Rimsky L, Vanveggel S, Stevens M. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: Week 48 phase III analysis. AIDS 2013;27:889-897.
5. Eviplera 200 mg/25mg/245mg film-coated tablets: Summary of Product Characteristics. Gilead Sciences International Limited. Cambridge, UK, December 2013.
6. COMPLERA-(emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets, for oral use. US Prescribing Information. Gilead Sciences, Inc. Foster City, CA. Revised June 2013.
7. Behrens G, Rijnders B, Nelson M, et al. Week 48 Efficacy and Safety of Rilpivirine (RPV) versus Efavirenz (EFV) plus Emtricitabine/Tenofovir DF (FTC/TDF) in Treatment-Nai?ve, HIV-1 Infected Patients with Baseline Viral Load £ 100,000 copies/mL: Pooled ECHO and THRIVE Analysis [Poster TUPE023]. Paper presented at: XIX International AIDS Conference; July 22-27, 2012, Washington, D.C.
8. Tambuyzer L, Azijn H, Rimsky LT, et al. Compilation and prevalence of mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2009;14:103-109.
9. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-246.
10. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background necleoside or necleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): A phase 3, randomised, non-inferiority trial. Lancet 2011;378:229-237.
11. Rimsky L, Van Eygen V, Hoogstoel A, et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther 2013;18:967-977.
12. Division of Acquired Immune Deficiency Syndrome (DAIDS). Division of Acquired Immune Deficiency Syndrome (DAIDS) table for grading the severity of adult and pediatric adverse events. Clarification August 2009. 1 ed: Regulatory Support Center, 2004.
13. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-145.
14. Antinori A, Angeletti C, Ammassari A, et al. Adherence in HIV-Positive Patients Treated With Single Tablet Regimens and Multi-Pill Regimens. Findings from the COMPACT Study [Poster P014]. Paper presented at: HIV 11, 2011, Glasgow, U.K.
15. Vera J, Aragao F, Guimaraes M, Vaz Pinto I. Benefits of ART simplification on adherence, clinical and economic outcomes [Poster P005]. Paper presented at: HIV 11, 2011, Glasgow, U.K.
16. Cohen C, Davis KL, Meyers JL. Association of Partial Adherence to Antiretroviral Therapy with Hospitalizations and Healthcare Costs in an HIV Population [Poster Presentation P001]. Paper presented at 11th International Congress on Drug Therapy in HIV Infection; November 11-15, 2012, Glasgow, U.K.
17. Maggiolo F, Di Matteo S, Masini G, et al. Cost-effectiveness analysis of first line HAART [Poster Abstract P96]. Paper presented at: HIV 11, 2012, Glasgow, U.K.
18. Cohen C, Wohl D, Arribas J, et al. STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/ Emtricitabine/Tenofovir DF in ART-Nai?ve Adults-Week 48 Results [Poster Number O425]. Paper presented at: 11th International Congress on Drug Therapy in HIV Infection; November 11-15, 2012, Glasgow, U.K.
19. Rockstroh JK, Dejesus E, Henry K, et al. A randomized, double-blind comparison of co-formulated elvitegravir/co bicistat/emtricitabine/tenofovir versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr 2013;62:483-486.
20. Zolopa A, Sax PE, Dejesus E, et al. A randomized, doubleblind comparison of co-formulated elvitegravir/cobicistat/ emtricitabine/tenofovir DF versus efavirenz/emtricitabine/ tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr 2013;63:96-100.